Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus - Wikidata - awgldk - TriplyDB

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

http://www.wikidata.org/entity/Q28246766

about

The role of genetic variation near interferon-kappa in systemic lupus erythematosus Type I interferonopathies in pediatric rheumatology Inflammatory cytokines in systemic lupus erythematosus Immunomodulatory functions of type I interferons The regulation of inflammation by interferons and their STATs Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus Targeting dendritic cell function during systemic autoimmunity to restore tolerance Current perspectives on systems immunology approaches to rheumatic diseases.The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development Constitutive type I interferon modulates homeostatic balance through tonic signaling Gene expression profiles in a rabbit model of systemic lupus erythematosus autoantibody production Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy.Assessing the human immune system through blood transcriptomics.Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus.Genetic regulation of serum cytokines in systemic lupus erythematosus Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome.Interferon-alpha: a therapeutic target in systemic lupus erythematosus A genomic approach to human autoimmune diseases.Pathways: Strategies for susceptibility genes in SLE.Type I interferon in the pathogenesis of lupus.Interferon alpha in systemic lupus erythematosus Interferons and their stimulated genes in the tumor microenvironment Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus.Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy.Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures.Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort Plasmacytoid dendritic cells: recent progress and open questions Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.Two major autoantibody clusters in systemic lupus erythematosus Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes.IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells.Targeting of type I interferon in systemic autoimmune diseases Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis.Cytokines in Sjogren's syndrome: potential therapeutic targets.Current and novel therapeutics in the treatment of systemic lupus erythematosus Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment.Biologic therapy for autoimmune diseases: an update.

P2860

Q21296846-55E49DDE-DE55-4AEB-A905-549455B6AC18 Q26748746-AB58463F-0227-4D7E-AE96-45B5666C967F Q26823647-6E3F6408-BFD2-49BA-AEF2-03CD83D4E1B9 Q26823904-0896BFD3-A790-4F1E-86F3-F890CC65EA76 Q26829387-CACEA87D-9DD7-40A6-B473-A410DC57027E Q27677078-4930FB9F-C519-445F-B3F4-131F4C3FC017 Q27687098-0C223990-0999-426C-9C4E-05683F6DDDC0 Q27687400-CE8DB01E-01ED-405A-940F-773E8D3C5985 Q28076264-08D03703-A8BE-4552-9E0C-AE762510DDDB Q28084276-931794D7-C7C4-4F90-B859-FAA4C798EF46 Q28260631-D2761630-5FB5-4ACD-B056-728CF4720516 Q30496834-94AADD64-D7CC-4D06-B3D3-A58E66E3299D Q33534742-F37B8503-DFDD-44AE-886B-87C69440A84B Q33629522-536DA9C0-A760-42C6-8459-21EBAB275125 Q33637845-5FD6AFE9-AD53-43E3-A628-DFE91DF2398F Q33682879-28534B6A-4B6A-4FC5-B66B-A4B98FD5C07E Q33715480-95FC4924-C33B-4695-95C2-1936FAB489CA Q33744320-81DE892D-D301-4A00-9A2A-315E56FA515E Q33762839-A514493F-DE29-4C6F-A425-A5229382E929 Q33843583-5EECB404-CD6D-40FF-B297-C2A564FFBE58 Q33852174-AFAB9440-273F-44F0-B1F8-0DC9BF1BEC69 Q33961179-470BE2C8-C777-440D-99FA-826797DB4941 Q33988567-81F1E833-DA7F-4881-8977-C8B2E74A478B Q34017633-592B644C-EA67-482F-A2CC-492F0CB1493F Q34027485-ECB6E40A-CEA1-4C63-8CF4-A9C94A8058FF Q34106220-8D8A38B4-33F1-42BA-A337-FEC8BEC90BA5 Q34123569-FD947F9C-2952-48B1-9EFA-47993762F5F7 Q34149941-76B9F603-5C3B-4ECF-8086-D372BCC2A97C Q34161393-012D3A7E-C26F-44EB-BCAF-39D6D699503D Q34162925-15307C82-CB7C-49B4-B086-6279D7B71508 Q34170097-87283C8B-84C7-42C5-B5B4-F89B5A872D7E Q34171558-1AA09251-2465-4606-9194-5ECCD750EBD3 Q34240254-E500AE58-4C4C-4A4C-B31A-C357D6067783 Q34420821-722D8E78-21D6-45BC-8844-6B5C3A7EFA8E Q34451758-3F8BD2D6-D295-4F1E-9AD4-36979B817B90 Q34535634-493DEF29-0827-4E6A-9F4A-5B23E9E14E6C Q34601660-ECD6D7A1-99D6-40A0-B8DD-7E29DB00660A Q34648851-1A6B0A0C-4BFB-4933-8AB0-18AD392ED439 Q34650870-39534787-8AD5-457A-A735-3BCBD4AA2545 Q34655597-E99FF3B0-9F60-4B71-B456-941C8245DB56

P2860

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

http://www.wikidata.org/entity/Q28246766

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Neutralization of interferon-a ...... n systemic lupus erythematosus

@ast

Neutralization of interferon-a ...... n systemic lupus erythematosus

@en

Neutralization of interferon-a ...... n systemic lupus erythematosus

@nl

type

label

Neutralization of interferon-a ...... n systemic lupus erythematosus

@ast

Neutralization of interferon-a ...... n systemic lupus erythematosus

@en

Neutralization of interferon-a ...... n systemic lupus erythematosus

@nl

prefLabel

Neutralization of interferon-a ...... n systemic lupus erythematosus

@ast

Neutralization of interferon-a ...... n systemic lupus erythematosus

@en

Neutralization of interferon-a ...... n systemic lupus erythematosus

@nl

P1433

Q28246766-0E255386-14A9-4E94-8144-9A5CA47F3F34

P1476

Q28246766-4FB692F4-07A4-4F93-A3BD-C44E276E9BF7

P2093

Q28246766-1AB13A5B-0121-485B-8022-1F34ED062E3E

Q28246766-2F1B691E-0214-4FF1-8724-6BC8B5DB971D

Q28246766-31D2B0DD-BABD-4FBD-8E97-BFE0FA41A7F7

Q28246766-3381E5DF-3B68-4974-87B7-FDC313C25532

Q28246766-7C0C991A-EA95-4C08-A195-37FB223FD720

Q28246766-8935776B-21C4-4D1B-84B5-03CDD410A4A2

Q28246766-951EEAD5-3293-48E4-BFEF-46B57C1A96DF

Q28246766-978096C7-E74E-4960-BD2D-CC26F092AB5D

Q28246766-CE4AEA1B-B6A7-4415-B1E5-F707DA2576CD

Q28246766-CFBED6A1-ED30-41C1-958F-391182B220A1

P304

Q28246766-735D76BC-818B-4B49-AB49-3C522B93659F

P31

Q28246766-1B8CF978-3BB6-4251-B66D-1EA9CA7283DF

P3181

Q28246766-A453A353-B483-4BFD-A01A-D7BE2638E3B2

P356

Q28246766-84F5E55A-7CFF-4A41-92ED-4433B8BB92F3

P407

Q28246766-2AE2ED1B-7F98-4CAB-B8FA-51928C43DD3E

P433

Q28246766-7287D09F-5328-42D3-B88E-5F42C824FAA5

P478

Q28246766-0F32B2A4-F0CF-47EE-82D9-BC3CC3D95BC5

P577

Q28246766-E2F5D768-F810-4401-BCA3-62153307E6AA

P5875

Q28246766-64697F67-9A8A-4E24-9CE4-EF9BC8434F5B

P698

Q28246766-0D4047F1-5448-4CCA-81E5-E60ABE6B98F4

P921

Q28246766-17C2F6B2-66F5-4CB0-ABD7-5D73A874B196

Q28246766-876A616C-03D1-4994-9973-0DA0AC91E42F

P3181

P356

P1433

Arthritis & Rheumatology

P1476

Neutralization of interferon-a ...... n systemic lupus erythematosus

@en

P2093

Anthony J Coyle

http://www.w3.org/2001/XMLSchema#string

Bahija Jallal

http://www.w3.org/2001/XMLSchema#string

Barbara White

http://www.w3.org/2001/XMLSchema#string

Brandon W Higgs

http://www.w3.org/2001/XMLSchema#string

Christopher A Morehouse

http://www.w3.org/2001/XMLSchema#string

Jianliang Zhang

http://www.w3.org/2001/XMLSchema#string

Laura Richman

http://www.w3.org/2001/XMLSchema#string

Melissa de los Reyes

http://www.w3.org/2001/XMLSchema#string

Peter A Kiener

http://www.w3.org/2001/XMLSchema#string

Philip Brohawn

http://www.w3.org/2001/XMLSchema#string

P304

1785-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1035972

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/ART.24557

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26250844

http://www.w3.org/2001/XMLSchema#string

P698

19479852

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial